The m6A modification is closely related to the most promising immunotherapies, such as anti-PD-1 (program cell death ligand 1)/PD-L1 (programmed death ligand 1) monotherapy, cancer vaccines, and big data virtual screening. The gene discussed is CD274; the disease is cancer.